INV10 11:30-12:00
Axel Schambach, Hannover Medical School ⓘ
From CARs to TRUCKs: Towards next-generation immunotherapeutics
INV11 12:00-12:30
Hélène Nègre, Servier ⓘ
T2EVOLVE: Standardization of preclinical and clinical development of engineered T-cell therapy in Europe—a cross-functional multi-stakeholder initiative
INV12 12:30-13:00
Els Verhoeyen, CIRI, ENS de Lyon and C3M, Nice ⓘ
Novel lentiviral pseudotypes for T and NK cell gene therapy and ‘nanoblades’ for efficient gene editing in hematopoietic gene therapy target cells.
OR07 13:00-13:15
Adrien Krug, Université Côte d'Azur/C3M
CD8-targeted lentiviral vectors to generate CAR T cells in vivo as treatment for T cell lymphoma
OR08 13:15-13:30
Ugo Hirigoyen, Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA
Characterization of tumor extracellular vesicles produced during oncolytic infection